Ibrutinib, Bruton’s tyrosine kinase inhibitor, for non-Hodgkin lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Thomas J. Kipps, MD, PhD, of the University of California, San Diego, San Diego, CA, discusses the currently available data on the safety and efficacy of ibrutinib, a first-in-class, oral, irreversible inhibitor of Bruton’s tyrosine kinase, for the treatment of patients with non-Hodgkin lymphoma, including mantle cell lymphoma, Waldenstrom macroglobulinemia and diffuse large B-cell lymphoma.

Share this video